Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Hyderabad-based Dr Reddy’s Laboratories (DRL), which aspires to break into the top 5 among domestic pharma companies, has been strengthening its portfolio through in-licensing opportunities and partnerships. However, the essentially acute-therapy-focused company is now eyeing inorganic growth in the medium term to boost its chronic portfolio, a fast-growing evergreen segment of the Indian pharma market.

Speaking to Business Standard, MV Ramana, chief executive officer, branded markets (India and emerging markets), Dr Reddy’s Laboratories (DRL), said that they are indeed scouting for inorganic opportunities to add to their India growth plans.

“We want to grow our existing base business and also focus on